Detail of "226256-56-0"

Reference

Misconceptions about calcimimetics

All Rights Reserved. Misconceptions about calcimimetics. Nemeth, E. F. (NPS Pharmaceuticals, Inc. 226256-56-0 and 9002-64-6 are cas registry numbers. These chemicals are also mentioned in this article., Toronto, ON M5G 1L8, Can.). Annals of the New York Academy of Sciences, 1068(Skeletal Development and Remodeling in Health, Disease, and Aging), 471-476 (English) 2006 New York Academy of Sciences. CODEN: ANYAA9. ISSN: 0077-8923. DOCUMENT TYPE: Journal; General Review CA Section: 1 (Pharmacology) A review. Calcimimetics are ligands that activate the calcium receptor. Some are small mols. and of these, the most extensively studied are phenylalkylamines like cinacalcet. This compd. is a pos. allosteric modulator that selectively targets the parathyroid calcium receptor to inhibit the secretion of parathyroid hormone. Cinacalcet is the first calcimimetic compd. to attain regulatory approval for the treatment of hyperparathyroidism resulting from end-stage renal disease. The discovery of calcimimetics and the receptor they act on are considered with the intent of extg. lessons relevant to medical research and the discovery of new drugs. .

Hypercalcemia Due to Resistant Hyperparathyroidism in Renal Transplant Patients Treated With the Calcimimetic Agent Cinacalcet

All Rights Reserved. Hypercalcemia Due to Resistant Hyperparathyroidism in Renal Transplant Patients Treated With the Calcimimetic Agent Cinacalcet. Apostolou, T.; Kollia, K.; Damianou, L.; Kaitsioti, H.; Kotsiev, V.; Dracopoulos, S.; Vougas, V.; Hadjiconstantinou, V. (Department of Nephrology, Transplant Unit, Evangelismos General Hospital, Athens, Greece). Transplantation Proceedings, 38(10), 3514-3516 (English) 2006 Elsevier Inc. CODEN: TRPPA8. ISSN: 0041-1345. DOCUMENT TYPE: Journal CA Section: 1 (Pharmacology) Introduction and aims: Calcimimetic agents increase the sensitivity of calcium-sensing receptors of parathyroid glands and suppress both serum calcium levels and parathyroid hormone (PTH). The use of these drugs in patients with a functioning graft suffering from resistant hyperparathyroidism and hypercalcemia is still under investigation. We report seven patients who were treated with the calcimimetic agent cinacalcet.In this article, certain chemicals are used. Some of their cas registry numbers are 9002-64-6 and 226256-56-0 Methods: The four male and three female patients of 38 to 72 years of age received a renal transplant from 4 to 35 mo before cinacalcet treatment. Serum creatinine was 1.2 to 1.8 mg/dL (estd. glomerular filtration rate between 40 and 75 mL/min). Immunosuppressive treatment consisted of interleukin-2 antibody induction therapy, calcineurin inhibitors (cyclosporine or tacrolimus), prednisolone, and mycophenolate mofetil. Mild to severe hyperparathyroidism resistant to vitamin D analog treatment (intact parathyroid hormone mol. [iPTH] 174 to 519 pg/mL) was accompanied by severe hypercalcemia (Ca >11 mg%). To date the patients have completed 3 to 18 mo of therapy. Cinacalcet 30 mg/d was initially administered. Results: This treatment resulted in a rapid decrease in total serum calcium (8.6 to 9.2 mg/dL) while PTH showed a milder, progressive decrease. Having controlled calcium levels, 1a OH vitamin D (0.25 mg/d per os) was added to the treatment, which resulted in a further decline of iPTH without producing an increase in serum calcium concns. (median initial iPTH value 401 pg/mL, median value after treatment 176 pg/mL). Therapy was well tolerated without hypocalcemic events. Conclusion: Cinacalcet offered a better holistic treatment approach to such patients. .